

## PACIFIC EDGE FULL YEAR RESULT TO BE ANNOUNCED 25 MAY 2023

Cancer diagnostics company Pacific Edge Limited (NZX:PEB) advises that its full year results for the 12 months to 31 March 2023 (FY23) will be released on Thursday 25 May 2023, prior to 10am.

This will be followed by an Investor and Analyst conference call at 11.00am (NZST). This investor briefing will be available via webcast by the following link: [www.virtualmeeting.co.nz/pebfy23](http://www.virtualmeeting.co.nz/pebfy23) or by phone on the following toll free numbers:

New Zealand: 0800 449 170  
Australia: 1800 896 574

### Questions

Questions can be submitted online in writing via the Webcast platform or verbally via the audio call system when prompted.

If you have any queries regarding the results announcement or the conference call, please contact Stacey Stanley on 03 479 5807 or [stacey.stanley@pefnz.com](mailto:stacey.stanley@pefnz.com).

ENDS

### Approved for release by:

Grant Gibson  
Chief Financial Officer  
Pacific Edge Ltd  
P: +64 (3) 479 5800

### OVERVIEW [www.pacificedge.co.nz](http://www.pacificedge.co.nz) [www.pacificedgedx.com](http://www.pacificedgedx.com)

Pacific Edge Limited (NZX/ ASX: PEB) is a global cancer diagnostics company leading the way in the development and commercialisation of bladder cancer diagnostic and prognostic tests for patients presenting with hematuria or surveillance of recurrent disease. Headquartered in Dunedin, New Zealand, the company provides its suite of Cxbladder tests globally through its wholly owned, and CLIA certified, laboratories in New Zealand and the USA.

### ABOUT CXBLADDER [www.cxbladder.com](http://www.cxbladder.com)

Cxbladder is a non-invasive genomic urine test optimized for the detection and management of bladder cancer. The Cxbladder evidence portfolio developed over the past 14 years includes more than 20 peer reviewed publications for primary detection, surveillance, adjudication of atypical urine cytology and equivocal cystoscopy. Cxbladder is the focal point of numerous ongoing and planned clinical studies to generate an ever-increasing body of clinical utility evidence supporting adoption and use in the clinic to improve patient health outcomes. Cxbladder is reimbursed by CMS and has been trusted by over 2,000 US urologists in the diagnosis and management of more than 80,000 patients, including the option for in-home sample collection. In New Zealand, Cxbladder is accessible to 70% of the population via public healthcare and all residents have the option of buying the test online.